News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tarix Pharmaceuticals' TXA127 Granted Orphan Drug Status for Treatment of Pulmonary Arterial Hypertension


9/27/2011 10:17:43 AM

CAMBRIDGE, Mass., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Tarix Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted TXA127, the Company's lead peptide drug candidate, orphan drug status for the treatment of pulmonary arterial hypertension (PAH). Emerging science has demonstrated that the naturally occurring peptide angiotensin (1-7), the pharmaceutical ingredient in TXA127, exhibits a protective effect in animal models of PAH, suggesting a potentially beneficial role for TXA127 against this disease.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES